Clinical Trial

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）

Study acronym: UNIGUIDE-1
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This multicenter, randomized, double-Blind, parallel-group, placebo-controlled phase III trial is to evaluate the efficacy and safety of UBT251 Injection in patients with Type 2 Diabetes Mellitus with inadequate glycemic control on diet and exercise alone
Trial Details
NCT Number NCT07659574
Lead Sponsor The United Bio-Technology (Hengqin) Co., Ltd.
Conditions Type 2 Diabetes
Enrollment 360 participants
Start Date 2026-08-10
Primary Completion 2027-09-24 (estimated)
Study Completion 2027-10-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-22